ClinicalTrials.gg
Not yet recruitingNCT07815626Updated Sep 11, 2026

Phase 3 Study to Evaluate the Efficacy and Safety of Human Growth Hormone Injection (Sinotropin AQ) for the Treatment of Children With Idiopathic Short Stature

A Phase 3 interventional study of Human Growth Hormone (hGH) and Human Growth Hormone (hGH) in Idiopathic Short Stature (ISS), sponsored by Zhongshan Sansure Hygene Biomedicine Co., Ltd.. Not yet recruiting at 34 sites in China. Open to participants aged 3 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Zhongshan Sansure Hygene Biomedicine Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
3 Years to 11 Years
Sex
All
01

Study summary

This study is a multicenter, randomized, open-label, active-controlled, non-inferiority Phase III clinical trial. It aims to evaluate the efficacy and safety of Human Growth Hormone (hGH) Injection (Sinotropin AQ) in pediatric participants with Idiopathic Short Stature (ISS). Eligible participants will be randomized to receive either the study drug or an active comparator for 52 weeks. The primary efficacy endpoint is height velocity (HV, cm/year) over the treatment period. The study drug will be administered subcutaneously once daily at a dose of 0.15 IU/kg. The results of this trial will provide evidence on whether hGH Injection represents an effective and safe treatment option for improving height in children with ISS.

02

Conditions studied

  • Idiopathic Short Stature (ISS)

Keywords

  • Idiopathic Short Stature
  • ISS
03

In context

Lead sponsor

This is the only study on the registry with Zhongshan Sansure Hygene Biomedicine Co., Ltd. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Tanner stage I (prepubertal) at : males aged 3 to \<11 years ; females aged 3 to \<10 years ;
  • 2. At screening, height \< -2 standard deviations (SD) for age and sex (height reference per Appendix 1);
  • 3. Peak GH ≥10.0 ng/mL in any growth hormone (GH) stimulation test;
  • 4. Bone age minus chronological age ≤ 1 year.

Exclusion criteria

Exclusion Criteria:

  • 1.Closed epiphyses (skeletally mature);
  • 2.Severe allergic diathesis, or known to growth hormone or any of its ;
  • 3.History of or current active malignancy;
  • 4.Systemic chronic diseases, including but not limited to moderate-to-severe anemia, hypothyroidism, chronic kidney disease, cardiovascular disease (e.g., dilated cardiomyopathy), psychiatric disorders, or congenital anomalies that require clinical intervention per the investigator's judgment.
  • 5.Patients with a prior diagnosis of intracranial hypertension;
  • 6.Patients with congenital skeletal dysplasia, or scoliosis ≥15° (or moderate or greater), limping (gait disturbance), and patients with a prior diagnosis of slipped capital femoral epiphysis ;
  • 7.Other types of growth and developmental disorders, including confirmed or highly suspected growth hormone deficiency (GHD), Noonan syndrome, Prader-Willi syndrome, Russell-Silver syndrome, Turner syndrome, small for gestational age (SGA), short stature due to SHOX gene defects, and short stature of other identified causes;
  • 8. Patients with a confirmed diagnosis of diabetes mellitus, or fasting blood glucose ≥6.1 mmol/L on two consecutive measurements.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Human growth hormone Injection(Investigational product)

    This product is human growth hormone (hGH) injection (Sinotropin AQ). Usage and dosage: 0.15 IU/kg/day (0.05 mg/kg/day), once daily, administered by subcutaneous injection.

    Drug: Human Growth Hormone (hGH)

  • Active comparator
    human growth hormone(hGH) injection(reference product)

    This product is human growth hormone (hGH) injection. Usage and dosage: 0.15 IU/kg/day (0.05 mg/kg/day), once daily, administered by subcutaneous injection.

    Drug: Human Growth Hormone (hGH)

Interventions

  • This product is human growth hormone (hGH) injection (Sinotropin AQ). Usage and dosage: 0.15 IU/kg/day (0.05 mg/kg/day), once daily, administered by subcutaneous injection.

  • This product is human growth hormone (hGH) injection. Usage and dosage: 0.15 IU/kg/day (0.05 mg/kg/day), once daily, administered by subcutaneous injection

06

What researchers measure

Primary outcomes

  1. The value of Annual Height velocity

    The value of Annual Height velocity (HV, cm/year)

    Time frame: At the end of 52 weeks of treatment

Secondary outcomes

  1. The change of ΔHT SDS value

    The change from baseline in height SDS (ΔHT SDS)

    Time frame: At all visit points from baseline to week 52

  2. The change of IGF-1 SDS value

    The change of insulin-like growth factor-1 standard deviation score value

    Time frame: At all visit points from baseline to Week 52

  3. The change of height velocity value (ΔHV)

    The change from baseline in height velocity(ΔHV)

    Time frame: At all visit points from baseline to Week 52

  4. The change of bone age relative to change of chronological age(ΔBA/ΔCA) value

    The change of bone age (BA) relative to the change in chronological age (CA) from basline to end of 52-week treatment

    Time frame: At all visit points from basline to week 52

  5. The safety of human growth hormone injection

    Evaluate all TEAEs, SAEs, and clinically significant abnormalities in laboratory tests, vital signs, and physical examination.

    Time frame: Baseline, Week 13, Week 26, Week 39, and Week 52

  6. Immunogenicity of Human Growth Hormone Injection

    Assessment of anti-GH and neutralizing antibody incidence

    Time frame: At all visit points from baseline to week 52

07

Study locations

34 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Oct 2028, 25 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2026
First posted
Sep 11, 2026
StartEst.
Sep 2026
Primary completionEst.
Oct 2028
CompletionEst.
Feb 2029
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07815626
Lead sponsor
Zhongshan Sansure Hygene Biomedicine Co., Ltd.
Responsible party
Sponsor
First posted
Sep 11, 2026
Start date
Sep 2026 (estimated)
Primary completion
Oct 2028 (estimated)
Completion
Feb 2029 (estimated)
Last update
Sep 11, 2026

Study contacts

Jian Qi
Contact
jian.qi@sansure.com
+86 13581831286

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion